Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia
出版年份 2020 全文链接
标题
Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia
作者
关键词
-
出版物
Small
Volume 16, Issue 31, Pages 2001890
出版商
Wiley
发表日期
2020-07-01
DOI
10.1002/smll.202001890
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- AML: New Drugs but New Challenges
- (2020) Alan Burnett et al. Clinical Lymphoma Myeloma & Leukemia
- PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion
- (2019) Tony Andreas Müller et al. LEUKEMIA
- Modulators of CXCR4 and CXCR7/ACKR3 function
- (2019) Ilze Adlere et al. MOLECULAR PHARMACOLOGY
- A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
- (2018) David Martínez-Cuadrón et al. ANNALS OF HEMATOLOGY
- CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance
- (2018) Xiaojia Hu et al. CANCER LETTERS
- Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell
- (2018) Jonathan Hoggatt et al. CELL
- Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma
- (2018) Eudocia Q Lee et al. CLINICAL CANCER RESEARCH
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
- (2018) Ya-Zhen Qin et al. Blood Cancer Journal
- Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
- (2018) Prajwal Boddu et al. Frontiers in Oncology
- Functional genomic landscape of acute myeloid leukaemia
- (2018) Jeffrey W. Tyner et al. NATURE
- D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia
- (2017) Ikuko Omori et al. EXPERIMENTAL HEMATOLOGY
- Relevance of Half-Life in Drug Design
- (2017) Dennis A. Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
- (2017) Darja Karpova et al. Journal of Translational Medicine
- The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
- (2017) M Abraham et al. LEUKEMIA
- A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
- (2017) Ravi Salgia et al. LUNG CANCER
- A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Co
- (2017) Todd M. Cooper et al. PEDIATRIC BLOOD & CANCER
- Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
- (2017) Sheng-Bin Peng et al. Oncotarget
- Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia
- (2016) Breanne Landry et al. JOURNAL OF CONTROLLED RELEASE
- A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
- (2016) John D. Hainsworth et al. Targeted Oncology
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- Dynamic Biostability, Biodistribution, and Toxicity of l/d-Peptide-Based Supramolecular Nanofibers
- (2015) Cuihong Yang et al. ACS Applied Materials & Interfaces
- Acute myeloid leukemia-Major progress over four decades and glimpses into the future
- (2015) Hagop Kantarjian AMERICAN JOURNAL OF HEMATOLOGY
- Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy
- (2015) B.-S. Cho et al. BLOOD
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks
- (2015) F Guo et al. ONCOGENE
- A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells
- (2015) Jing Yu et al. Oncotarget
- Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis
- (2015) Xiaojin Li et al. Scientific Reports
- Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
- (2014) S.-B. Peng et al. MOLECULAR CANCER THERAPEUTICS
- Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
- (2014) K. Beider et al. MOLECULAR CANCER THERAPEUTICS
- A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo
- (2014) Xiaojin Li et al. Scientific Reports
- HPMA Copolymer CXCR4 Antagonist Conjugates Substantially Inhibited the Migration of Prostate Cancer Cells
- (2014) Zheng-Hong Peng et al. ACS Macro Letters
- Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
- (2013) K. Beider et al. CLINICAL CANCER RESEARCH
- The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
- (2013) A. Peled et al. CLINICAL CANCER RESEARCH
- Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia
- (2013) Amnon Peled et al. Theranostics
- A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia
- (2012) G. L. Uy et al. BLOOD
- In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer
- (2012) Duha Fahham et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice
- (2011) L. Zhao et al. BLOOD
- The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome
- (2011) D. C. Dale et al. BLOOD
- The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation
- (2011) M Mohty et al. LEUKEMIA
- Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia
- (2011) S Wakita et al. LEUKEMIA
- C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice
- (2011) Y.-Y. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
- (2010) Iskra Pusic et al. CURRENT OPINION IN HEMATOLOGY
- CXCR4 chemokine receptor antagonists: perspectives in SCLC
- (2009) Jan A Burger et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Specific Interactions between the Viral Coreceptor CXCR4 and the Biguanide-Based Compound NB325 Mediate Inhibition of Human Immunodeficiency Virus Type 1 Infection
- (2008) N. Thakkar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
- (2008) S. M. Devine et al. BLOOD
- Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
- (2008) B. Nervi et al. BLOOD
- The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation
- (2008) S Tavor et al. LEUKEMIA
- CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers
- (2008) J A Burger et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started